The usual bit of truth tortured into a lie. OK. At least one IPF patient treated with pirfenidone suffered nausea so devastating that it was clearly preferable to stop treatment. What do we learn from this?
The japan study said that spO2 was best indicator of QOL, thats why they used that initially as the primary endpoint, but then in the middle of the trial, they changed the primary endpoint to VC, or something, and surprise surprise, but there was no change in spO2 at the end of the study. Therefore QOL is not improved. read pages 46-58 of the japan study. This really should be considered a failed study too, because of the changes of primary endpoints in the middle of the study. imo